MoonLake Immunotherapeutics (NASDAQ:MLTX – Get Free Report) and Longeveron (NASDAQ:LGVN – Get Free Report) are both medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their valuation, analyst recommendations, profitability, earnings, dividends, risk and institutional ownership.
Analyst Ratings
This is a summary of current recommendations and price targets for MoonLake Immunotherapeutics and Longeveron, as reported by MarketBeat.
Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
MoonLake Immunotherapeutics | 0 | 4 | 9 | 0 | 2.69 |
Longeveron | 0 | 0 | 2 | 0 | 3.00 |
MoonLake Immunotherapeutics presently has a consensus target price of $78.67, suggesting a potential upside of 68.13%. Longeveron has a consensus target price of $8.00, suggesting a potential upside of 292.16%. Given Longeveron’s stronger consensus rating and higher possible upside, analysts clearly believe Longeveron is more favorable than MoonLake Immunotherapeutics.
Earnings and Valuation
Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
MoonLake Immunotherapeutics | N/A | N/A | -$36.01 million | ($0.75) | -62.39 |
Longeveron | $1.23 million | 10.54 | -$21.41 million | ($9.61) | -0.21 |
Longeveron has higher revenue and earnings than MoonLake Immunotherapeutics. MoonLake Immunotherapeutics is trading at a lower price-to-earnings ratio than Longeveron, indicating that it is currently the more affordable of the two stocks.
Insider and Institutional Ownership
93.8% of MoonLake Immunotherapeutics shares are owned by institutional investors. Comparatively, 10.0% of Longeveron shares are owned by institutional investors. 12.0% of MoonLake Immunotherapeutics shares are owned by insiders. Comparatively, 19.1% of Longeveron shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.
Profitability
This table compares MoonLake Immunotherapeutics and Longeveron’s net margins, return on equity and return on assets.
Net Margins | Return on Equity | Return on Assets | |
MoonLake Immunotherapeutics | N/A | -7.92% | -7.76% |
Longeveron | -2,129.24% | -300.96% | -164.96% |
Risk & Volatility
MoonLake Immunotherapeutics has a beta of 1.25, indicating that its share price is 25% more volatile than the S&P 500. Comparatively, Longeveron has a beta of 0.43, indicating that its share price is 57% less volatile than the S&P 500.
Summary
MoonLake Immunotherapeutics beats Longeveron on 7 of the 13 factors compared between the two stocks.
About MoonLake Immunotherapeutics
MoonLake Immunotherapeutics, a clinical-stage biopharmaceutical company, engages in developing therapies. It develops Sonelokimab, a novel investigational Nanobody for the treatment of inflammation diseases; and hidradenitis suppurativa, psoriatic arthritis, axial spondyloarthritis, and psoriasis. MoonLake Immunotherapeutics was incorporated in 2020 and is headquartered in Zug, Switzerland.
About Longeveron
Longeveron Inc., a clinical stage biotechnology company, develops cellular therapies for aging-related and life-threatening conditions in the United States and Japan. The company's lead investigational product is the LOMECEL-B, an allogeneic mesenchymal stem cell formulation sourced from the bone marrow of young and healthy adult donors. It is conducting Phase 1, Phase 1/2, Phase 2a, and Phase 2b clinical trials in various indications, such as aging-related frailty, alzheimer's disease, and hypoplastic left heart syndrome. The company was incorporated in 2014 and is headquartered in Miami, Florida.
Receive News & Ratings for MoonLake Immunotherapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MoonLake Immunotherapeutics and related companies with MarketBeat.com's FREE daily email newsletter.